Vimarsana
Biggest News Aggregation in the World

Page 48 - Loss Attributable News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Loss Attributable. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Loss Attributable Today - Breaking & Trending Today

BEST Inc. Announces Unaudited First Quarter 2022 Financial Results - Vimarsana News

BEST Inc. Announces Unaudited First Quarter 2022 Financial Results

/PRNewswire/ -- BEST Inc. (NYSE: BEST) ("BEST" or the "Company"), a leading integrated smart supply chain solutions and logistics services provider in China...

BEST Inc. Announces Unaudited First Quarter 2022 Financial Results - Vimarsana News

BEST Inc. Announces Unaudited First Quarter 2022 Financial Results

/PRNewswire/ -- BEST Inc. (NYSE: BEST) ("BEST" or the "Company"), a leading integrated smart supply chain solutions and logistics services provider in China...

nCino Reports First Quarter Fiscal Year 2023 Financial Results - Vimarsana News

nCino Reports First Quarter Fiscal Year 2023 Financial Results

01.06.2022 - Total Revenues of $94.2M, up 51% year-over-year Subscription Revenues of $79.2M, up 55% year-over-yearOrganic Subscription Revenues of $65.6M, up 29% year-over-year WILMINGTON, N.C., June 01, 2022 (GLOBE NEWSWIRE) - nCino, Inc. (NASDAQ: NCNO), a ...

BIT Mining Limited Announces Unaudited Financial Results for the First Quarter ended March 31, 2022 - Vimarsana News

BIT Mining Limited Announces Unaudited Financial Results for the First Quarter ended March 31, 2022

/PRNewswire/ -- BIT Mining Limited (NYSE: BTCM) ("BIT Mining," "the Company," "we," "us," or "our company"), a leading technology-driven cryptocurrency mining...

Ryvu Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update - Vimarsana News

Ryvu Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...